Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab
dc.contributor.author | Woxholt, Sindre | |
dc.contributor.author | Ueland, Thor | |
dc.contributor.author | Aukrust, Pål | |
dc.contributor.author | Anstensrud, Anne Kristine | |
dc.contributor.author | Broch, Kaspar | |
dc.contributor.author | Tøllefsen, Ingvild Maria | |
dc.contributor.author | Ryan, Liv | |
dc.contributor.author | Bendz, Bjørn | |
dc.contributor.author | Hopp, Einar | |
dc.contributor.author | Kløw, Nils-Einar | |
dc.contributor.author | Seljeflot, Ingebjørg | |
dc.contributor.author | Halvorsen, Bente | |
dc.contributor.author | Dahl, Tuva Børresdatter | |
dc.contributor.author | Huse, Camilla | |
dc.contributor.author | Andersen, Geir Øystein | |
dc.contributor.author | Gullestad, Lars | |
dc.contributor.author | Wiseth, Rune | |
dc.contributor.author | Amundsen, Brage H. | |
dc.contributor.author | Damås, Jan Kristian | |
dc.contributor.author | Kleveland, Ola | |
dc.date.accessioned | 2023-09-26T10:45:26Z | |
dc.date.available | 2023-09-26T10:45:26Z | |
dc.date.created | 2023-09-11T10:42:48Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Open heart. 2023, 10 (2), . | en_US |
dc.identifier.issn | 2053-3624 | |
dc.identifier.uri | https://hdl.handle.net/11250/3092016 | |
dc.description.abstract | Background Tocilizumab improves myocardial salvage index (MSI) in patients with ST-elevation myocardial infarction (STEMI), but its mechanisms of action are unclear. Here, we explored how cytokines were affected by tocilizumab and their correlations with neutrophils, C-reactive protein (CRP), troponin T, MSI and infarct size. Methods STEMI patients were randomised to receive a single dose of 280 mg tocilizumab (n=101) or placebo (n=98) before percutaneous coronary intervention. Blood samples were collected before infusion of tocilizumab or placebo at baseline, during follow-up at 24–36, 72–168 hours, 3 and 6 months. 27 cytokines were analysed using a multiplex cytokine assay. Cardiac MRI was performed during hospitalisation and 6 months. Results Repeated measures analysis of variance showed significant (p<0.001) between-group difference in changes for IL-6, IL-8 and IL-1ra due to an increase in the tocilizumab group during hospitalisation. IL-6 and IL-8 correlated to neutrophils in the placebo group (r=0.73, 0.68, respectively), which was attenuated in the tocilizumab group (r=0.28, 0.27, respectively). A similar pattern was seen for MSI and IL-6 and IL-8 in the placebo group (r=−0.29, –0.25, respectively) in patients presenting ≤3 hours from symptom onset, which was attenuated in the tocilizumab group (r=−0.09,–0.14, respectively). Conclusions Tocilizumab increases IL-6, IL-8 and IL-1ra in STEMI. IL-6 and IL-8 show correlations to neutrophils/CRP and markers of cardiac injury in the placebo group that was attenuated in the tocilizumab group. This may suggest a beneficial effect of tocilizumab on the ischaemia-reperfusion injury in STEMI patients. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | BMJ Publishing Group | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab | en_US |
dc.title.alternative | Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.source.pagenumber | 0 | en_US |
dc.source.volume | 10 | en_US |
dc.source.journal | Open heart | en_US |
dc.source.issue | 2 | en_US |
dc.identifier.doi | 10.1136/openhrt-2023-002301 | |
dc.identifier.cristin | 2173892 | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 |